At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo
This agreement will enhance Lupin’s gastroenterology portfolio and expand its presence in emerging markets
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
BaseLaunch has supported 27 biotech companies across multiple modalities and indications
The update promises to revolutionize laboratory workflows by optimizing resources
The expansion includes a larger technical and service team and increased local procurement
The state-of-the-art facility is expected to be commissioned over the next three years
GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
The move strengthens GBL’s clinical-stage presence in the United States
Subscribe To Our Newsletter & Stay Updated
